Mass General Brigham Ventures
VC Fund
Cambridge, United States
Mass General Brigham Ventures is a VC fund in Cambridge focused on Health Care and Biotechnology. Mass General Brigham Ventures is the venture capital arm of Mass General Brigham that invests in early-stage companies. The primary mission of MGB Ventures is to accelerate the translation of innovative research and technology developed within the Mass General Brigham system into commercial solutions that can significantly improve patient care andhealthcare delivery.
- Total investments:
- 41
- Last investment:
- Lead investor:
- 10%
Last updated:
For AI agents: llms.txt
Industries Mass General Brigham Ventures invests in
Stages Mass General Brigham Ventures invests in
Countries Mass General Brigham Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Meredith Fisher
|
|||
Investment Focus
Industry
- Health Care 19 (46%)
- Biotechnology 17 (41%)
- Therapeutics 11 (27%)
- Medical 7 (17%)
- Life Science 4 (10%)
Stage
- Series A 14 (34%)
- Series B 11 (27%)
- Seed 6 (15%)
- Series C 5 (12%)
- Funding Round 2 (5%)
Country
- United States 24 (59%)
- France 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Meredith Fisher
Partner
|
Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Claris Biotherapeutics
|
Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars. The formulation creates a recombinant hepatocyte growth factor which accelerates the healing process, providing healthcare providers noninvasive therapeutic treatment. | $118M / Series B / Jul 28, 2026 | |
InStride Health
|
InStride Health provides evidence-based OCD and anxiety treatment to keep kids and teenagers engaged along the way. | $30M / Series C / Jun 15, 2026 | |
Violet Therapeutics
|
Violet Therapeutics is a healthcare company that operates in stealth mode. | $4.8M / Seed / May 13, 2026 | |
Nocion Therapeutics
|
Nocion Therapeutics is a developer of novel pharmaceuticals intended to treat the conditions arising from neurogenic inflammation. The company is developing "nocions" which are a new kind of therapy that selectively affects actively firing nociceptors, enabling patients to provide targeted, robust and sustained relief for the treatment ofserious conditions including cough, itch, pain and inflammation. | $23M / Series B / Jan 07, 2026 | |
Affinia Therapeutics
|
Affinia Therapeutics is a developer of a platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies intended to develop medicines for devastating diseases. The company leverages synthetic and systems biology combined with high-throughput screening and tissue and single-cell resolution for people affected by muscle andcentral nervous system (CNS) diseases with significant unmet needs, thereby providing medical professionals with the rational design of novel vectors and gene therapies with remarkably improved properties. | $40M / Series C / Oct 07, 2025 | |
Predicta Biosciences
|
Predicta Biosciences is a precision oncology firm that integrates multiomics and liquid biopsies to create diagnostic tools and therapies. They also have an in-house pipeline for novel immunotherapy targets in pre-clinical stages. | $23.4M / Series A / Oct 01, 2025 | |
Carta Healthcare
|
Carta empowers hospitals to personalize the delivery of care to the individual needs of each patient. The approach Carta Healthcare is advocating and enabling is to: find past patients similar to the current one being treated; quantify what exactly happened to them during their journey through the hospital (this is where our model comes in) and;use machine learning to project what the particular patient in question will need, and what the patient can expect their experience to be in the hospital. Carta was founded in 2017 and is based in Palo Alto, California, United States. | $18.3M / Series B / May 07, 2025 | |
Abcuro
|
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by its founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivovalidation in diseased tissue has uncovered new approaches to target key compartments of the immune system.The company was incorporated in 2015 and is based in Newton, Massachusetts. | $200M / Series C / Feb 12, 2025 | |
Rippl Care
|
Rippl, a mental health organization, is committed to assisting seniors who suffer from dementia and other neurocognitive disorders. | $23M / Series A / Oct 02, 2024 | |
Tuesday Health
|
Tuesday Health empowers lives through supportive care by easing the symptoms and stress of serious illness. | $60M / May 21, 2024 | |
| See all 41 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Mass General Brigham Ventures invest in?
Mass General Brigham Ventures invests primarily in Health Care, Biotechnology and Therapeutics startups, most often at Series A and Series B stage. Most of the 41 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Mass General Brigham Ventures?
Public channels for Mass General Brigham Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Mass General Brigham Ventures?
The team at Mass General Brigham Ventures includes Meredith Fisher (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
